<div id="readability-page-1"><div>Zydus Lifesciences has signed an agreement to acquire US-based Assertio Holdings in an all-cash deal worth about $166.4 million (Rs.1600 crore), marking a strategic push into specialty and oncology markets in the United States.Under the terms of the deal, Zydus will acquire all outstanding shares of Assertio at $23.50 per share, through a tender offer followed by a merger, the company said in a statement. The transaction is expected to close in FY27, subject to customary regulatory approvals and shareholder acceptance.Upon successful completion of the transaction, Assertio will be delisted from Nasdaq.Assertio has revenue of $68.23 million in 2025.Assertio is a specialty pharmaceutical company focused on oncology supportive care, with a commercial portfolio anchored by Rolvedon (eflapegrastim-xnst)—a long-acting G-CSF (Granulocyte Colony-Stimulating Factor) used to reduce infection risk in cancer patients undergoing chemotherapy. The drug works by stimulating the bone marrow to produce more white blood cells (neutrophils) to boost immunity. Rolvedon is an alternative to Neulasta (pegfilgrastim) and its biosimilar versions, having potentially lower injection site reactions and better insurance coverage.For Zydus, the acquisition offers immediate access to a ready-made US specialty commercial platform, including established oncology relationships and distribution capabilities. The company said it plans to leverage this infrastructure to scale its presence in the high-value specialty segment.“This transaction represents a strategic step in strengthening our specialty and oncology footprint in the US,” said Managing Director Sharvil Patel, adding that Assertio’s portfolio aligns with Zydus’s long-term strategy of building “differentiated, durable specialty businesses globally.”.The deal structure involves a tender offer where Zydus will seek to acquire a majority stake from shareholders, followed by a second-step merger to buy out remaining shares at the same price.Why the deal mattersThe acquisition is significant for Zydus as it accelerates its shift from generics to specialty therapies, particularly in the US where margins are higher but entry barriers are steeper. Instead of building commercial capabilities from scratch, the company gains instant access to a specialised oncology sales network and an approved biologic asset.Assertio’ s has over 170 community oncology accounts and buy-and-bill infrastructure offers a ready-made base to build a broader oncology platorm.It also strengthens Zydus’s position in oncology supportive care—a niche but growing segment—while providing a platform to cross-sell future products and expand its specialty pipeline in developed markets.More broadly, the move reflects a growing trend among Indian drugmakers to pivot toward complex generics, specialty drugs and biologics to offset pricing pressure in traditional generics.With the Assertio acquisition, Zydus is effectively buying not just a product portfolio but a commercial entry point into the US specialty market, positioning itself for higher-value growth beyond its core generics business.</div></div>

ASRT

LABU

Zydus Lifesciences has acquired US-based Assertio Holdings for approximately $166.4 million (Rs 1,600 crore) in an all-cash deal, enhancing its presence in the US specialty and oncology markets. The acquisition involves purchasing all outstanding shares at $23.50 each, with the deal expected to close in FY27 pending regulatory approvals. Assertio, known for its oncology supportive care drug Rolvedon, provides Zydus with immediate access to a specialized commercial platform and established oncology relationships, marking a strategic shift from generics to specialty therapies.

Zydus buys US specialty drugmaker Assertio in Rs 1,600 crore all-cash deal